News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2015

FDA requests further data for approval of Epigenomics’ blood-based colorectal cancer screening test

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 189 KB   Berlin, Germany, November 4, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX, ISIN: DE000A11QW50), announces that it has received a response letter from the U.S. Food and Drug Administration (FDA) in relation to its premarket approval […]

Read more

Epigenomics adjusts 2015 outlook after FDA response letter

PDF 74 KB   Berlin, Germany, November 4, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) adjusts its financial outlook for fiscal year 2015 following the FDA response letter on the Company’s lead product Epi proColon®. As communicated in the past, such a decision has a significant impact on the achievement of […]

Read more

Epigenomics AG to provide an update on blood-based epigenetic tests at the Association of Molecular Pathology (AMP) 2015 Annual Meeting

PDF 266 KB Berlin (Germany) and Germantown, MD (U.S.A.), November 2, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that it will host a corporate workshop at the Association for Molecular Pathology (AMP) 2015 Annual Meeting. Attendees of AMP, analysts, investors and media representatives are […]

Read more

Epigenomics AG Announces Q2 2015 and 6M 2015 Financial Results and Reports on Operational Highlights

PDF 297 KB Q2 2015 revenue increased by 20%, mainly driven by an increase in product sales of 36% European Commission granted up to EUR 2.8 million to Epigenomics for development of blood-based Epi proLung® test Epigenomics significantly improved its financial situation by raising EUR 5.0 million in a capital increase Epigenomics reaches nearly 100% […]

Read more

Epigenomics and BioChain Announce the Inclusion of their Proprietary Blood-based Septin9 Test in the Chinese Screening Guideline for Colorectal Cancer

PDF 311 KB Berlin (Germany), Germantown, MD, and Newark, CA (U.S.A.), Beijing (China), July 15, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, an early cancer diagnostic company with operations in both USA and China and Epigenomics’ exclusive strategic commercialization partner in China, today announced […]

Read more

Epigenomics AG Announces Q1 2015 Financial Results and Reports on Operational Highlights

PDF 329 KB   Epigenomics reaches 99.5% adherence for Epi proColon® in the ADMIT Trial BioChain starts to commercialize Epi proColon® in China Epigenomics receives EUR 2.8 million grant from European Commission to support development of Epi proLung® Solid financial position; liquidity at the end of period EUR 6.4 million; Up to EUR 5 million […]

Read more